Abstract
..
Main
..
RCT vs. Obs.
..
Feedback
Home
c19early.org COVID-19 treatment researchCasirivimab/imdevimabCasirivimab/i.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
 
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — Casirivimab/imdevimab reduced COVID-19 risk: real-time meta analysis of 31 studies

@CovidAnalysis, December 2024, Version 48V48
Post
Share
PDF
Studies
Feedback
https://c19early.org/rmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Regeneron (RCT) 38% 0.62 [0.29-1.33] recov. time 92 (n) 91 (n) Improvement, RR [CI] Treatment Control Regeneron (RCT) 54% 0.46 [0.19-1.13] recov. time 92 (n) 91 (n) Regeneron (RCT) 71% 0.29 [0.17-0.48] death/hosp. 18/1,355 62/1,341 Regeneron (RCT) 70% 0.30 [0.13-0.68] death/hosp. 7/736 24/748 Regeneron (RCT) 29% 0.71 [0.60-0.85] recov. time 1,355 (n) 1,341 (n) Regeneron (RCT) 29% 0.71 [0.60-0.85] recov. time 736 (n) 748 (n) Weinreich (RCT) 50% 0.50 [0.09-2.72] death 2/2,091 4/2,089 Weinreich (RCT) 67% 0.33 [0.03-3.17] death 1/1,355 3/1,341 Weinreich (RCT) -2% 1.02 [0.06-16.2] death 1/736 1/748 Weinreich (RCT) 71% 0.29 [0.17-0.48] death/hosp. 18/1,355 62/1,341 Weinreich (RCT) 70% 0.30 [0.13-0.68] death/hosp. 7/736 24/748 Weinreich (RCT) 29% 0.71 [0.58-0.87] recov. time 1,355 (n) 1,341 (n) Weinreich (RCT) 29% 0.71 [0.58-0.87] recov. time 736 (n) 748 (n) Webb 98% 0.0 [0.00-2e+05] death 0/115 57/5,536 Webb 91% 0.09 [0.01-0.63] hosp. 1/115 538/5,536 Cooper 77% 0.23 [0.03-1.65] death 1/1,148 33/8,534 Cooper 48% 0.52 [0.23-1.20] ICU 6/1,148 85/8,534 Cooper 52% 0.48 [0.35-0.64] hosp. 45/1,148 703/8,534 Kakinoki 58% 0.42 [0.17-0.92] progression 13/55 22/53 Komagamine 77% 0.23 [0.01-4.63] ventilation 0/53 2/75 Komagamine 92% 0.08 [0.01-0.90] ICU 0/53 7/75 Komagamine 68% 0.32 [0.13-0.68] progression 8/53 33/75 Komagamine 29% 0.71 [0.58-0.87] hosp. time 53 (n) 75 (n) Suzuki (PSM) -200% 3.00 [0.12-73.3] death 1/222 0/222 Suzuki 60% 0.40 [0.05-3.45] death 1/314 5/635 Suzuki (PSM) 45% 0.55 [0.31-0.96] progression 17/222 31/222 Suzuki 50% 0.50 [0.31-0.80] progression 34/314 70/365 O'Brien (DB RCT) 85% 0.15 [0.01-2.78] hosp. 0/100 3/104 O'Brien (DB RCT) 92% 0.08 [0.01-0.77] hosp./ER 0/100 6/104 O'Brien (DB RCT) 33% 0.67 [0.43-0.98] symp. case 29/100 44/104 O'Brien (DB RCT) 40% 0.60 [0.45-0.81] viral load 100 (n) 104 (n) Shopen -46% 1.46 [0.73-2.67] severe case 24/116 26/243 Osugi 24% 0.76 [0.23-2.49] hosp. 4/30 15/74 Wei 61% 0.39 [0.26-0.60] death/hosp. 23/1,116 27/5,291 Wei 61% 0.39 [0.30-0.51] hosp. 59/3,280 75/16,284 Wilden 82% 0.18 [0.05-0.50] hosp. n/a n/a Faraone 92% 0.08 [0.01-0.83] death 0/11 8/23 Faraone 94% 0.06 [0.00-0.76] oxygen 0/11 15/23 Miyashita 33% 0.67 [0.11-3.97] ventilation 2/461 3/461 Miyashita 46% 0.54 [0.35-0.82] oxygen 30/461 56/461 Levey 31% 0.69 [0.07-7.37] ICU 1/36 2/50 Levey 7% 0.93 [0.16-5.26] oxygen 2/36 3/50 Levey -108% 2.08 [0.81-5.33] hosp. 9/36 6/50 Kneidinger 97% 0.03 [0.00-264] severe case 0/3 34/215 Williams -21% 1.21 [0.14-9.86] oxygen 1/88 6/676 Williams -1% 1.01 [0.12-8.01] severe case 1/88 7/676 Williams 14% 0.86 [0.10-6.63] hosp. 1/88 8/676 Gershengorn -95% 1.95 [0.86-4.18] hosp. 369 (n) 5,915 (n) Gershengorn (PSM) -105% 2.05 [1.23-3.42] hosp. 21/369 41/1,476 Gershengorn (PSM) -100% 2.00 [0.99-4.06] hosp. 11/213 22/852 Gershengorn (PSM) -111% 2.11 [1.00-4.44] hosp. 10/156 19/624 Hussein (PSM) 60% 0.40 [0.38-0.42] death/hosp. population-based cohort Kip 46% 0.54 [0.41-0.71] death/hosp. 61/1,479 227/2,954 Horby (RCT) 6% 0.94 [0.86-1.02] death 943/4,839 1,029/4,946 Horby (RCT) -1% 1.01 [0.90-1.14] ventilation 484/4,556 488/4,642 Horby (RCT) 21% 0.79 [0.69-0.91] death 396/1,633 452/1,520 Horby (RCT) 13% 0.87 [0.73-1.05] ventilation 190/1,599 202/1,484 Somersa.. (DB RCT) 3% 0.97 [0.56-1.69] death 804 (n) 393 (n) Somersa.. (DB RCT) 36% 0.64 [0.44-0.93] death 59/804 45/393 Somersa.. (DB RCT) -57% 1.57 [0.93-2.64] death 44/110 13/51 Somersa.. (DB RCT) 3% 0.97 [0.53-1.76] death 13/23 7/12 Somersa.. (DB RCT) 31% 0.69 [0.50-0.95] death/int. 82/804 58/393 Somersa.. (DB RCT) 30% 0.70 [0.52-0.94] no disch. 90/804 63/393 McCreary (PSM) 93% 0.07 [0.01-0.51] death 1/652 29/1,304 McCreary (PSM) 56% 0.44 [0.28-0.68] death/hosp. 22/652 101/1,304 McCreary (PSM) 48% 0.52 [0.33-0.82] hosp. 22/652 85/1,304 McCreary (PSM) 40% 0.60 [0.43-0.85] hosp./ER 40/652 133/1,304 Iustila-Maran (ICU) -16% 1.16 [0.53-2.54] death 14/50 7/29 ICU patients Shah -14% 1.14 [0.45-2.91] death 8/50 7/50 Shah 0% 1.00 [0.41-2.46] ventilation 8/50 8/50 Shah 14% 0.86 [0.54-1.39] ICU 19/50 22/50 Shah -43% 1.43 [0.00-1565] ICU 50 (n) 50 (n) Shah 4% 0.96 [0.63-1.45] oxygen 23/50 24/50 Shah 12% 0.88 [0.60-1.28] hosp. time 50 (n) 50 (n) Regeneron (RCT) 94% 0.06 [0.01-0.50] symp. case 0/186 8/223 Regeneron (RCT) 48% 0.52 [0.25-1.07] cases 10/186 23/223 Regeneron (DB RCT) 92% 0.08 [0.01-0.79] hosp. 0/841 6/842 Regeneron (DB RCT) 81% 0.19 [0.12-0.30] cases 20/841 108/842 Regeneron (DB RCT) 82% 0.18 [0.08-0.41] cases 7/841 38/842 Regeneron (DB RCT) 89% 0.11 [0.01-2.06] hosp./ER 0/753 4/752 Regeneron (DB RCT) 81% 0.19 [0.10-0.35] symp. case 11/753 59/752 Regeneron (DB RCT) 62% 0.38 [0.23-0.61] recov. time 753 (n) 752 (n) Regeneron (DB RCT) 69% 0.31 [0.17-0.55] viral time 753 (n) 752 (n) Isa (DB RCT) 93% 0.07 [0.01-0.28] symp. case 3/729 13/240 Isa (DB RCT) 93% 0.07 [0.01-0.28] cases 0/729 10/240 Bes-Berlandier -67% 1.67 [0.69-4.06] progression 5/17 13/74 Isa (RCT) -37% 1.37 [0.57-3.32] symp. case 35/245 5/48 Casirivimab/imdevimab COVID-19 outcomes c19early.org December 2024 Favors casirivimab/im.. Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0